C. Beau Hilton

Dr. C. Beau Hilton

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ANAziz Nazha
Aziz Nazha
RKRami Komrokji
Rami Komrokji
MMManja Meggendorfer
Manja Meggendorfer
XJXuefei Jia
Xuefei Jia
NRNathan Radakovich
Nathan Radakovich
MSMikkael A. Sekeres
Mikkael A. Sekeres
PURPOSE: Patients with myelodysplastic syndromes (MDS) have a survival that can range from months to decades. Prognostic systems that incorporate advanced analytics of clinical, pathologic, and molecular data have the potential to more accurately and dynamically predict survival in patients receiving various therapies. METHODS: A total of 1,471 MDS patients with comprehensively annotated clinical and molecular data were included in a training cohort and analyzed using machine learning techniques. A random survival algorithm was used to build a prognostic model, which was then validated in external cohorts. The accuracy of the proposed model, compared with other established models, was assessed using a concordance (c)index. RESULTS: The median age for the training cohort was 71 years. Commonly mutated genes included SF3B1, TET2, and ASXL1. The algorithm identified chromosomal karyotype, platelet, hemoglobin levels, bone marrow blast percentage, age, other clinical variables, seven discrete gene mutations, and mutation number as having prognostic impact on overall and leukemia-free survivals. The model was validated in an independent external cohort of 465 patients, a cohort of patients with MDS treated in a prospective clinical trial, a cohort of patients with paired samples at different time points during the disease course, and a cohort of patients who underwent hematopoietic stem-cell transplantation. CONCLUSION: A personalized prediction model on the basis of clinical and genomic data outperformed established prognostic models in MDS. The new model was dynamic, predicting survival and leukemia transformation probabilities at different time points that are unique for a given patient, and can upstage and downstage patients into more appropriate risk categories.

3 April 2020 in npj Digital Medicine
Verified
Journal Article
Open access
CHC. Beau Hilton
C. Beau Hilton
AMAlex Milinovich
Alex Milinovich
CFChristina Felix
Christina Felix
NVNirav Vakharia
Nirav Vakharia
TCTimothy Crone
Timothy Crone
ANAziz Nazha
Aziz Nazha
Hospital systems, payers, and regulators have focused on reducing length of stay (LOS) and early readmission, with uncertain benefit. Interpretable machine learning (ML) may assist in transparently identifying the risk of important outcomes. We conducted a retrospective cohort study of hospitalizations at a tertiary academic medical center and its branches from January 2011 to May 2018. A consecutive sample of all hospitalizations in the study period were included. Algorithms were trained on medical, sociodemographic, and institutional variables to predict readmission, length of stay (LOS), and death within 48–72 h. Prediction performance was measured by area under the receiver operator characteristic curve (AUC), Brier score loss (BSL), which measures how well predicted probability matches observed probability, and other metrics. Interpretations were generated using multiple feature extraction algorithms. The study cohort included 1,485,880 hospitalizations for 708,089 unique patients (median age of 59 years, first and third quartiles (QI) [39, 73]; 55.6% female; 71% white). There were 211,022 30-day readmissions for an overall readmission rate of 14% (for patients ≥65 years: 16%). Median LOS, including observation and labor and delivery patients, was 2.94 days (QI [1.67, 5.34]), or, if these patients are excluded, 3.71 days (QI [2.15, 6.51]). Predictive performance was as follows: 30-day readmission (AUC 0.76/BSL 0.11); LOS > 5 days (AUC 0.84/BSL 0.15); death within 48–72 h (AUC 0.91/BSL 0.001). Explanatory diagrams showed factors that impacted each prediction.

29 October 2024 in PLOS Digital Health
Verified
Journal Article
Open access
PDF file
AVAlexander D. VanHelene
Alexander D. VanHelene
IKIshaani Khatri
Ishaani Khatri
CHC. Beau Hilton
C. Beau Hilton
SMSanjay Mishra
Sanjay Mishra
EUEce D. Gamsiz Uzun
Ece D. Gamsiz Uzun
JWJeremy L. Warner
Jeremy L. Warner
Meta-researchers commonly leverage tools that infer gender from first names, especially when studying gender disparities. However, tools vary in their accuracy, ease of use, and cost. The objective of this study was to compare the accuracy and cost of the commercial software Genderize and Gender API, and the open-source gender R package. Differences in binary gender prediction accuracy between the three services were evaluated. Gender prediction accuracy was tested on a multi-national dataset of 32,968 gender-labeled clinical trial authors. Additionally, two datasets from previous studies with 5779 and 6131 names, respectively, were re-evaluated with modern implementations of Genderize and Gender API. The gender inference accuracy of Genderize and Gender API were compared, both with and without supplying trialists’ country of origin in the API call. The accuracy of the gender R package was only evaluated without supplying countries of origin. The accuracy of Genderize, Gender API, and the gender R package were defined as the percentage of correct gender predictions. Accuracy differences between methods were evaluated using McNemar’s test. Genderize and Gender API demonstrated 96.6% and 96.1% accuracy, respectively, when countries of origin were not supplied in the API calls. Genderize and Gender API achieved the highest accuracy when predicting the gender of German authors with accuracies greater than 98%. Genderize and Gender API were least accurate with South Korean, Chinese, Singaporean, and Taiwanese authors, demonstrating below 82% accuracy. Genderize can provide similar accuracy to Gender API while being 4.85x less expensive. The gender R package achieved below 86% accuracy on the full dataset. In the replication studies, Genderize and gender API demonstrated better performance than in the original publications. Our results indicate that Genderize and Gender API achieve similar accuracy on a multinational dataset. The gender R package is uniformly less accurate than Genderize and Gender API.

20 September 2019 in JCO Precision Oncology
Verified
Journal Article
Open access
ANAziz Nazha
Aziz Nazha
MSMikkael A. Sekeres
Mikkael A. Sekeres
RBRafael Bejar
Rafael Bejar
MRMichael J. Rauh
Michael J. Rauh
MOMegan Othus
Megan Othus
JMJaroslaw P. Maciejewski
Jaroslaw P. Maciejewski
PURPOSE: We developed an unbiased framework to study the association of several mutations in predicting resistance to hypomethylating agents (HMAs) in patients with myelodysplastic syndromes (MDS), analogous to consumer and commercial recommender systems in which customers who bought products A and B are likely to buy C: patients who have a mutation in gene A and gene B are likely to respond or not respond to HMAs. METHODS: We screened a cohort of 433 patients with MDS who received HMAs for the presence of common myeloid mutations in 29 genes that were obtained before the patients started therapy. The association between mutations and response was evaluated by the Apriori market basket analysis algorithm. Rules with the highest confidence (confidence that the association exists) and the highest lift (strength of the association) were chosen. We validated our biomarkers in samples from patients enrolled in the S1117 trial. RESULTS: Among 433 patients, 193 (45%) received azacitidine, 176 (40%) received decitabine, and 64 (15%) received HMA alone or in combination. The median age was 70 years (range, 31 to 100 years), and 28% were female. The median number of mutations per sample was three (range, zero to nine), and 176 patients (41%) had three or more mutations per sample. Association rules identified several genomic combinations as being highly associated with no response. These molecular signatures were present in 30% of patients with three or more mutations/sample with an accuracy rate of 87% in the training cohort and 93% in the validation cohort. CONCLUSION: Genomic biomarkers can identify, with high accuracy, approximately one third of patients with MDS who will not respond to HMAs. This study highlights the importance of machine learning technologies such as the recommender system algorithm in translating genomic data into useful clinical tools.

11 October 2024 in Informatics in Medicine Unlocked
Verified
Journal Article
Open access
KLKyeryoung Lee
Kyeryoung Lee
HPHunki Paek
Hunki Paek
LHLiang-Chin Huang
Liang-Chin Huang
CHC. Beau Hilton
C. Beau Hilton
SDSurabhi Datta
Surabhi Datta
XWXiaoyan Wang
Xiaoyan Wang
Initial insights into oncology clinical trial outcomes are often gleaned manually from conference abstracts. We aimed to develop an automated system to extract safety and efficacy information from study abstracts with high precision and fine granularity, transforming them into computable data for timely clinical decision-making. We collected clinical trial abstracts from key conferences and PubMed (2012–2023). The SEETrials system was developed with three modules: preprocessing, prompt engineering with knowledge ingestion, and postprocessing. We evaluated the system’s performance qualitatively and quantitatively and assessed its generalizability across different cancer types— multiple myeloma (MM), breast, lung, lymphoma, and leukemia. Furthermore, the efficacy and safety of innovative therapies, including CAR-T, bispecific antibodies, and antibody-drug conjugates (ADC), in MM were analyzed across a large scale of clinical trial studies. SEETrials achieved high precision (0.964), recall (sensitivity) (0.988), and F1 score (0.974) across 70 data elements present in the MM trial studies Generalizability tests on four additional cancers yielded precision, recall, and F1 scores within the 0.979–0.992 range. Variation in the distribution of safety and efficacy-related entities was observed across diverse therapies, with certain adverse events more common in specific treatments. Comparative performance analysis using overall response rate (ORR) and complete response (CR) highlighted differences among therapies: CAR-T (ORR: 88 %, 95 % CI: 84–92 %; CR: 95 %, 95 % CI: 53–66 %), bispecific antibodies (ORR: 64 %, 95 % CI: 55–73 %; CR: 27 %, 95 % CI: 16–37 %), and ADC (ORR: 51 %, 95 % CI: 37–65 %; CR: 26 %, 95 % CI: 1–51 %). Notable study heterogeneity was identified (>75 % I2 heterogeneity index scores) across several outcome entities analyzed within therapy subgroups. SEETrials demonstrated highly accurate data extraction and versatility across different therapeutics and various cancer domains. Its automated processing of large datasets facilitates nuanced data comparisons, promoting the swift and effective dissemination of clinical insights.

1 February 2020 in Current Diabetes Reports
Verified
Journal Article
Closed access
PDF file
DBDavid T. Broome
David T. Broome
CHC. Beau Hilton
C. Beau Hilton
NMNeil Mehta
Neil Mehta